Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

Original Article

I. Ray-Coquard, P. Pautier, S. Pignata, D. Pérol, A. González-Martín, R. Berger, K. Fujiwara, I. Vergote, N. Colombo, J. Mäenpää, F. Selle, J. Sehouli, D. Lorusso, E.M.G. Alía, A. Reinthaller, S. Nagao, C. Lefeuvre-Plesse, U. Canzler, G. Scambia, A. Lortholary, F. Marmé, P. Combe, N.d. Gregorio, M. Rodrigues, P. Buderath, C. Dubot, A. Burges, B. You, E. Pujade-Lauraine, and P. Harter

N Engl J Med 2019;381:2416-2428

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation
Course opens: 
12/18/2019
Course expires: 
12/19/2021

Available Credit

  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation

Course closed

This course closed on Sunday, December 19, 2021 - 11:59pm.